The ALPPS procedure: hepatocellular carcinoma as a main indication. An Italian single-center experience.


Journal

Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 14 05 2018
accepted: 10 09 2018
pubmed: 27 9 2018
medline: 30 7 2019
entrez: 27 9 2018
Statut: ppublish

Résumé

The ALPPS is a technique that allows achieving hepatic resection by a rapid future liver remnant hypertrophy. The aim of this study was to report the experience of an Italian center with ALPPS in patients with liver tumors. A retrospective analysis of patients undergoing ALPPS between 2012 and 2017 was performed. Patients' characteristics and disease presentation, increase in future liver remnant (FLR) as well as intraoperative and postoperative short- and long-term outcomes were evaluated. A total of 24 patients underwent the ALPPS procedure: 17 procedures for hepatocarcinoma (HCC), 5 for colorectal liver metastases (CRLM), 1 for cholangiocarcinoma (CC) and 1 for Merkel Cell Carcinoma liver metastasis (MCCLM). Macrovascular invasion (MVI) was recorded in 10 (41.6%) patients: 8 (33.3%) patients with HCC had invasion of portal vein (5), middle hepatic vein (2) and inferior vena cava (1). One patient with CRLM had involvement of middle hepatic vein and one patient with CC had involvement of right portal vein and middle hepatic vein. A p-ALPPS in 14 cases (58.3%), 10 t-ALPPS (41.6%) and hanging maneuver in 19 patients (80%) were performed. Median postoperative stay was 26 days (range 16-68 days). 90-day mortality was 8.3% (two patients, one with CC and one with HCC), 90-day mortality for HCC was 5.8%. After stage 1, we counted 15 complications all of grade I; after stage 2 the number of complications was increased to 37:33 were of grade I and 4 were of grade IV. R0 resection was achieved in all patients with 100% oncology feasibility. After a median follow-up of 10 months (range 2-54), disease recurrence has been recorded in 6 patients with HCC and in 2 with CRLM. Eleven patients died, nine affected by HCC, one by CRLM, and one by CC. 2-years OS and disease-free survival (DFS) for the entire group were 47.3% and 47.5%, respectively. Concerning patients operated on for HCC, the 2-years OS and DFS were 38.5% and 60%, respectively. The ALPPS procedure is an interesting approach for large primary or secondary liver tumor with small FLR above all for large HCC associated with MVI, with acceptable OS and DFS.

Identifiants

pubmed: 30255436
doi: 10.1007/s13304-018-0596-3
pii: 10.1007/s13304-018-0596-3
doi:

Types de publication

Journal Article

Langues

eng

Pagination

67-75

Références

J Am Coll Surg. 2013 Jul;217(1):126-33; discussion 133-4
pubmed: 23632095
Br J Surg. 2010 Feb;97(2):240-50
pubmed: 20087967
Liver Int. 2017 Dec;37(12):1869-1876
pubmed: 28609020
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
HPB (Oxford). 2015 Jun;17(6):477-84
pubmed: 25728543
Int J Surg. 2016 Jun;30:38-44
pubmed: 27112834
World J Surg. 2014 Jun;38(6):1510-9
pubmed: 24748319
Hepatobiliary Pancreat Dis Int. 2016 Jun;15(3):319-23
pubmed: 27298110
Ann Surg. 2016 Jan;263(1):e11
pubmed: 25371131
Int J Surg. 2015 Jan;13:90-91
pubmed: 25500565
Ann Surg. 2003 Feb;237(2):208-17
pubmed: 12560779
Ann Surg Oncol. 2015 Sep;22(9):3109-20
pubmed: 25448799
Am J Surg. 2009 May;197(5):686-90
pubmed: 19249737
J Gastrointest Surg. 2013 Jan;17(1):207-12
pubmed: 22996934
Ann Surg Oncol. 2015;22(6):1933-42
pubmed: 25564160
Oncotarget. 2017 Sep 28;8(65):109723-109731
pubmed: 29312642
J Hepatol. 2016 Nov;65(5):938-943
pubmed: 27266618
World J Surg. 2014 Jun;38(6):1498-503
pubmed: 24146197
Ann Surg. 2008 Jan;247(1):49-57
pubmed: 18156923
HPB (Oxford). 2016 May;18(5):419-27
pubmed: 27154805
Int J Surg Case Rep. 2016;26:113-7
pubmed: 27484960
Ann Surg. 2003 May;237(5):686-91; discussion 691-3
pubmed: 12724635
Ann Surg. 2012 Mar;255(3):405-14
pubmed: 22330038
Ann Surg. 2016 Feb;263(2):e14-6
pubmed: 26079914
World J Surg. 2014 Jun;38(6):1504-9
pubmed: 24326456
Updates Surg. 2017 Mar;69(1):9-19
pubmed: 27766595
Ann Surg. 2015 Apr;261(4):e90-2
pubmed: 25706390
Eur J Surg Oncol. 2015 May;41(5):674-82
pubmed: 25630689
Surg Innov. 2017 Aug;24(4):358-364
pubmed: 28689487
J Gastrointest Surg. 2013 Apr;17(4):814-21
pubmed: 23188224
Updates Surg. 2017 Sep;69(3):411-419
pubmed: 28795384
Ann Surg Oncol. 2016 Apr;23(4):1335-43
pubmed: 26646946

Auteurs

Giovanni Vennarecci (G)

Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Circ.ne Gianicolense 87, 00151, Rome, Italy. gvennarecci@scamilloforlanini.rm.it.

Daniele Ferraro (D)

Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Circ.ne Gianicolense 87, 00151, Rome, Italy.

Antonella Tudisco (A)

Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Circ.ne Gianicolense 87, 00151, Rome, Italy.

Giovanni Battista Levi Sandri (GB)

Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Circ.ne Gianicolense 87, 00151, Rome, Italy.

Nicola Guglielmo (N)

Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Circ.ne Gianicolense 87, 00151, Rome, Italy.

Giammauro Berardi (G)

Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Circ.ne Gianicolense 87, 00151, Rome, Italy.

Isabella Sperduti (I)

Biostatistical Unit, Regina Elena National Cancer Institute, Rome, Italy.

Giuseppe Maria Ettorre (GM)

Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Circ.ne Gianicolense 87, 00151, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH